CR20200527A - Compuestos dirigidos a brm y metodos de uso asociados - Google Patents

Compuestos dirigidos a brm y metodos de uso asociados

Info

Publication number
CR20200527A
CR20200527A CR20200527A CR20200527A CR20200527A CR 20200527 A CR20200527 A CR 20200527A CR 20200527 A CR20200527 A CR 20200527A CR 20200527 A CR20200527 A CR 20200527A CR 20200527 A CR20200527 A CR 20200527A
Authority
CR
Costa Rica
Prior art keywords
target protein
present disclosure
brm
compounds
binds
Prior art date
Application number
CR20200527A
Other languages
English (en)
Inventor
Huifen Chen
Peter DRAGOVICH
Andrew P Crew
Jing Wang
Leanna Staben
Michael Berlin
Original Assignee
Arvinas Operations Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvinas Operations Inc, Genentech Inc filed Critical Arvinas Operations Inc
Publication of CR20200527A publication Critical patent/CR20200527A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>La presente descripción se refiere a compuestos bifuncionales, que son útiles como moduladores de SMARCA2 o BRM (proteína diana). En particular, la presente descripción se refiere a compuestos bifuncionales, que contienen en un extremo un ligando que se une a la ligasa de ubiquitina E3 de Von Hippel-Lindau, y en el otro extremo una porción que se une a la proteína diana, de manera que 5 la proteína diana se coloca en la proximidad de la ligasa de ubiquitina para efectuar la degradación (e inhibición) de la proteína diana. La presente descripción exhibe un amplio intervalo de actividades farmacológicas asociadas con la degradación/inhibición de la proteína diana. Las enfermedades o trastornos que resultan de la agregación o acumulación de la proteína diana se tratan o se previenen con los compuestos y composiciones de la presente descripción.</p>
CR20200527A 2018-04-01 2019-04-01 Compuestos dirigidos a brm y metodos de uso asociados CR20200527A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862651186P 2018-04-01 2018-04-01
US201962797754P 2019-01-28 2019-01-28
PCT/US2019/025254 WO2019195201A1 (en) 2018-04-01 2019-04-01 Brm targeting compounds and associated methods of use

Publications (1)

Publication Number Publication Date
CR20200527A true CR20200527A (es) 2021-04-09

Family

ID=66175525

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200527A CR20200527A (es) 2018-04-01 2019-04-01 Compuestos dirigidos a brm y metodos de uso asociados

Country Status (29)

Country Link
US (2) US20190300521A1 (es)
EP (2) EP3774789B1 (es)
JP (3) JP7721270B2 (es)
KR (2) KR102697733B1 (es)
CN (2) CN120504668A (es)
AU (3) AU2019249849C1 (es)
BR (1) BR112020020196A2 (es)
CA (1) CA3094305A1 (es)
CL (1) CL2020002546A1 (es)
CO (1) CO2020013762A2 (es)
CR (1) CR20200527A (es)
DK (1) DK3774789T3 (es)
ES (1) ES3027032T3 (es)
FI (1) FI3774789T3 (es)
HR (1) HRP20250617T1 (es)
HU (1) HUE071391T2 (es)
IL (1) IL277677B1 (es)
LT (1) LT3774789T (es)
MX (2) MX2020010368A (es)
MY (1) MY198308A (es)
PE (1) PE20212108A1 (es)
PH (1) PH12020500663A1 (es)
PL (1) PL3774789T3 (es)
PT (1) PT3774789T (es)
RS (1) RS66841B1 (es)
SG (1) SG11202008898UA (es)
SI (1) SI3774789T1 (es)
UA (1) UA130603C2 (es)
WO (1) WO2019195201A1 (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
AU2019249849C1 (en) * 2018-04-01 2022-09-29 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
US12539292B2 (en) 2018-04-01 2026-02-03 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
SG11202104495YA (en) * 2018-04-26 2021-05-28 Aurigene Discovery Tech Ltd Pyridazine derivatives as smarca2/4 degraders
WO2019213005A1 (en) * 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
WO2020160192A1 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020160193A2 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
KR102947433B1 (ko) 2019-04-12 2026-04-06 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
US12624044B2 (en) 2019-06-10 2026-05-12 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
WO2021022163A2 (en) 2019-07-31 2021-02-04 Foghorn Therapeutics Inc. Compounds and uses thereof
JP7502425B2 (ja) * 2019-10-01 2024-06-18 アルヴィナス・オペレーションズ・インコーポレイテッド Ｂｒｍ標的化化合物および関連使用方法
IL292153A (en) 2019-10-16 2022-06-01 Cemm Forschungszentrum Fur Molekulare Medizin Gmbh Oxazole and thiazole type choline ubiquitin ligase ring compounds and uses thereof
MX2022004526A (es) 2019-10-17 2022-07-21 Arvinas Operations Inc Moléculas bifuncionales que contienen una porción de unión a la ligasa de ubiquitina e3 unida a una porción de direccionamiento a bcl6.
EP4054724A4 (en) * 2019-10-28 2023-12-27 C4 Therapeutics, Inc. BIFUNCTIONAL CONNECTIONS
CN114728936A (zh) * 2019-10-29 2022-07-08 豪夫迈·罗氏有限公司 用于治疗癌症的双功能化合物
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
CA3167166A1 (en) * 2020-01-10 2021-07-15 Amgen Inc. Smarca2-vhl degraders
IL295176A (en) * 2020-01-29 2022-09-01 Foghorn Therapeutics Inc compounds and their uses
US12528825B2 (en) 2020-01-29 2026-01-20 Foghorn Therapeutics Inc. Compounds and uses thereof
MX2022009308A (es) 2020-01-29 2022-08-22 Foghorn Therapeutics Inc Compuestos y usos de estos.
WO2021163302A1 (en) * 2020-02-12 2021-08-19 Dana-Farber Cancer Institute, Inc. Compounds, compositions, and methods for protein degradation
CN119823124A (zh) 2020-03-05 2025-04-15 C4医药公司 用于brd9的靶向降解的化合物
PT4161935T (pt) * 2020-06-09 2025-08-14 Prelude Therapeutics Inc Compostos direcionados a brm e métodos de utilização associados
IL299860A (en) 2020-07-21 2023-03-01 Genentech Inc Antibody-conjugated chemical factors for the discharge of BRM and their methods
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
MX2023001445A (es) * 2020-08-04 2023-05-08 Aurigene Oncology Ltd Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4.
CN116490186B (zh) 2020-08-05 2025-10-31 C4医药公司 用于ret的靶向降解的化合物
WO2022099117A1 (en) 2020-11-06 2022-05-12 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
US12606568B2 (en) 2020-12-09 2026-04-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
US20240343724A1 (en) * 2020-12-09 2024-10-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
TW202241855A (zh) * 2021-01-27 2022-11-01 美商富曼西公司 用於防治無脊椎有害生物之唑類化合物
CN118388454A (zh) 2021-04-16 2024-07-26 阿尔维纳斯运营股份有限公司 Bcl6蛋白水解的调节剂和其相关使用方法
US20240287076A1 (en) 2021-05-05 2024-08-29 Biogen Ma Inc. Compounds for targeting degradation of bruton's tyrosine kinase
CR20230518A (es) * 2021-05-10 2024-02-13 Foghorn Therapeutics Inc Compuestos y usos de estos
CN117337178A (zh) * 2021-05-10 2024-01-02 福宏治疗公司 化合物及其用途
US11767330B2 (en) 2021-07-06 2023-09-26 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
WO2023283372A1 (en) 2021-07-07 2023-01-12 Biogen Ma Inc. Compounds for targeting degradation of irak4 proteins
CA3224732A1 (en) 2021-07-07 2023-01-12 Kevin M. Guckian Compounds for targeting degradation of irak4 proteins
WO2023287787A1 (en) 2021-07-13 2023-01-19 Prelude Therapeutics, Incorporated Brm targeting compounds and associated methods of use
CN118696045A (zh) * 2021-11-23 2024-09-24 南京再明医药有限公司 Brm选择性降解剂化合物及其应用
CN118679160A (zh) 2021-11-24 2024-09-20 阿维纳斯运营公司 Brm靶向化合物和相关的使用方法
JP2024541479A (ja) 2021-11-24 2024-11-08 アルビナス・オペレーションズ・インコーポレイテッド Ｂｒｍ標的化化合物及び関連使用方法
AU2022415778A1 (en) * 2021-12-14 2024-07-04 Prazer Therapeutics Inc. Novel compound for degrading target protein or polypeptide by using polyubiquitination
JP2025502782A (ja) * 2021-12-28 2025-01-28 ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム がん治療剤としての強力かつ選択的なｓｍａｒｃａ２分解キメラ分子
AR128331A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
AR128330A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
AU2023295547A1 (en) 2022-06-16 2025-01-09 Prelude Therapeutics Incorporated Kat6 targeting compounds with ubiquitin ligase binding moiety
CN119384414A (zh) * 2022-06-30 2025-01-28 甘李药业股份有限公司 一种用作smarca2/4抑制剂的化合物及其应用
CN115353468B (zh) * 2022-08-19 2023-06-30 安阳工学院 一种对甲苯磺酰氧基取代低聚乙二醇丙酸叔丁酯的制备方法
US20240190886A1 (en) 2022-11-15 2024-06-13 Prelude Therapeutics Incorporated BRM Targeting Compounds and Associated Methods of Use
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
CN120752233A (zh) * 2023-02-28 2025-10-03 上海海雁医药科技有限公司 取代的三环衍生物及其药物组合物和用途
TW202502750A (zh) 2023-06-08 2025-01-16 美商新銳思生物製藥股份有限公司 Smarca2之雙官能選擇性降解劑及其治療用途
WO2024256574A1 (en) * 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors
PE20260307A1 (es) 2023-06-14 2026-02-11 Astrazeneca Ab Degradadores de smarca2 y usos de estos
IL325247A (en) 2023-06-14 2026-02-01 Astrazeneca Ab History of 3-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-8,3-diazabicyclo[3.2.1]octane as a protacs from SMARCA2 joints for cancer treatment
CN121620368A (zh) * 2023-06-16 2026-03-06 普莱克斯姆公司 降解swi/snf相关基质相关联肌动蛋白依赖性染色质调控因子a亚家族的化合物和药物组合物
WO2025085738A1 (en) 2023-10-18 2025-04-24 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2025094065A1 (en) * 2023-11-01 2025-05-08 Aurigene Oncology Limited Amino-substituted pyridazine compounds as smarca2 and/or smarca4 degraders
CN122341612A (zh) 2023-11-10 2026-07-03 普莱鲁德疗法有限公司 靶向kat6的化合物
WO2025106637A1 (en) * 2023-11-16 2025-05-22 Foghorn Therapeutics Inc. Cinnoline derivatives useful as baf modulators
AU2024405980C1 (en) * 2023-12-22 2026-07-30 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Bicyclic fused heteroaromatic ring derivative, and pharmaceutical composition and use thereof
WO2025193454A1 (en) 2024-03-01 2025-09-18 Prelude Therapeutics Incorporated Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
WO2025189056A1 (en) 2024-03-08 2025-09-12 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease
WO2026120044A1 (en) 2024-12-04 2026-06-11 Astrazeneca Ab Smarca2 degraders and uses thereof
WO2026128580A2 (en) 2024-12-11 2026-06-18 Nurix Therapeutics, Inc. Bifunctional selective degraders of smarca2 and therapeutic uses thereof
WO2026136866A1 (en) 2024-12-20 2026-06-25 Prelude Therapeutics Incorporated Kat6 targeting compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP3370115A1 (en) 2003-12-03 2018-09-05 Nikon Corporation Exposure apparatus, exposure method and method for producing a device
KR102438072B1 (ko) * 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
EP4649963A3 (en) * 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． ターゲティングされたアンドロゲン受容体分解のための化合物および方法
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
AU2016232705C1 (en) 2015-03-18 2021-06-17 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
EP3319944A4 (en) * 2015-07-10 2019-04-24 Arvinas, Inc. MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
CA2988436A1 (en) * 2015-07-13 2017-01-19 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
BR112018008918A8 (pt) * 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
IL319363A (en) 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
CN107698657A (zh) * 2017-09-26 2018-02-16 中国药科大学 基于vhl配体和bet抑制剂诱导bet降解的双功能分子及其制备和应用
AU2019249849C1 (en) * 2018-04-01 2022-09-29 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use

Also Published As

Publication number Publication date
CN112166114B (zh) 2024-11-19
LT3774789T (lt) 2025-06-25
CN120504668A (zh) 2025-08-19
IL277677A (en) 2020-11-30
ES3027032T3 (en) 2025-06-12
BR112020020196A2 (pt) 2021-01-26
PL3774789T3 (pl) 2025-08-18
AU2019249849B2 (en) 2022-03-17
AU2022204042A1 (en) 2022-06-30
PE20212108A1 (es) 2021-11-04
US20240076295A1 (en) 2024-03-07
MY198308A (en) 2023-08-22
NZ767872A (en) 2024-04-26
FI3774789T3 (fi) 2025-06-17
HUE071391T2 (hu) 2025-08-28
IL277677B1 (en) 2026-08-01
PT3774789T (pt) 2025-05-28
KR102697733B1 (ko) 2024-08-26
RU2020135754A3 (es) 2022-05-04
WO2019195201A1 (en) 2019-10-10
KR20240130153A (ko) 2024-08-28
EP4537905A2 (en) 2025-04-16
HRP20250617T1 (hr) 2025-07-18
UA130603C2 (uk) 2026-04-01
EP3774789B1 (en) 2025-03-05
AU2024203058A1 (en) 2024-05-30
DK3774789T3 (da) 2025-06-10
SG11202008898UA (en) 2020-10-29
PH12020500663A1 (en) 2021-06-07
SI3774789T1 (sl) 2025-07-31
KR20210005037A (ko) 2021-01-13
EP4537905A3 (en) 2025-06-25
JP2023071767A (ja) 2023-05-23
RS66841B1 (sr) 2025-06-30
CL2020002546A1 (es) 2021-01-29
AU2024203058B2 (en) 2026-07-02
JP7721270B2 (ja) 2025-08-12
MX2020010368A (es) 2021-01-08
JP2021520350A (ja) 2021-08-19
CO2020013762A2 (es) 2021-01-18
MX2024000329A (es) 2024-01-25
RU2020135754A (ru) 2022-05-04
CA3094305A1 (en) 2019-10-10
CN112166114A (zh) 2021-01-01
AU2019249849C1 (en) 2022-09-29
EP3774789A1 (en) 2021-02-17
JP2025143253A (ja) 2025-10-01
AU2019249849A1 (en) 2020-10-01
US20190300521A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
PH12020500663A1 (en) Brm targeting compounds and associated methods of use
MX2019005007A (es) Protac dirigidos a la proteína tau y métodos asociados de uso.
MX2023004018A (es) Moduladores de la proteolisis del receptor de estrogeno y metodos asociados de uso.
MX2022010583A (es) Derivados de tetrahidronaftaleno y tetrahidroisoquinolina como degradores del receptor de estrogeno.
WO2019195609A3 (en) Modulators of proteolysis and associated methods of use
NZ787624A (en) Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety
MX2024015414A (es) Compuestos policiclicos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma rapidamente acelerado
MX2023009031A (es) Compuestos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma acelerado rapidamente.
WO2018119441A8 (en) Egfr proteolysis targeting chimeric molecules and associated methods of use
MX385750B (es) Compuestos y métodos para la degradación mejorada de proteinas específicas.
MX2022014548A (es) Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
JOP20210130A1 (ar) مثبطات apol1 وطرق استخدامها
EP4234030A3 (en) Pd-1/pd-l1 inhibitors
EP4600247A3 (en) Pd-1/pd-l1 inhibitors
MX387318B (es) Moduladores de la proteólisis basados en imida y métodos de uso asociados.
BR112022012410A2 (pt) Degradadores smarca e usos dos mesmos
MX389264B (es) Moduladores de proteolisis basados en imida y metodos de uso asociados.
EP4026835A3 (en) Pd-1/pd-l1 inhibitors
BR112017022349A2 (pt) ?composto, composição, método, e, método para inibir uma proteína irak?
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
BR112018068703A2 (pt) inibidores substituídos de menin-mll e métodos de uso
BR112015011760A2 (pt) composto, uso do composto, e uso de uma composição farmacêutica
CL2022001452A1 (es) Inhibidores de masp-2 y métodos de uso.
EA201900561A1 (ru) Конъюгаты циклодекстрин-белок-лекарственное средство
EA201892376A1 (ru) Комбинированный состав трех противовирусных соединений